Exagen Diagnostics

Exagen Inc. is a commercial-stage diagnostics company with a mission to address unmet needs in autoimmune disease management through specialized laboratory testing. Its core achievement is the development and commercialization of the AVISE test portfolio, anchored by its proprietary Cell-Bound Complement Activation Products (CB-CAPs) technology, which improves diagnostic accuracy for conditions like lupus. The company's strategy focuses on deepening adoption within rheumatology, expanding its test menu, and leveraging its laboratory capabilities to support biopharma clinical trials and data analytics. Despite commercial execution challenges reflected in its current valuation, Exagen maintains a focused position in the autoimmune diagnostics niche.

Proprietary biomarker discovery and assay development platform centered on Cell-Bound Complement Activation Products (CB-CAPs), which are stable, cell-surface-bound biomarkers of complement system dysregulation in autoimmune diseases like lupus.

Exagen competes with large national reference laboratories (Quest, LabCorp) with broad reach, specialized autoimmune test kit manufacturers (Werfen, Euroimmun), and emerging multi-omics diagnostic platforms. Its defensibility lies in proprietary CB-CAPs IP, deep rheumatology focus, and clinically validated tests, but it must continuously demonstrate superior utility to maintain its niche.